Cancers (Jul 2021)
Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
- Candice Hober,
- Lisa Fredeau,
- Anne Pham-Ledard,
- Marouane Boubaya,
- Florian Herms,
- Philippe Celerier,
- François Aubin,
- Nathalie Beneton,
- Monica Dinulescu,
- Arnaud Jannic,
- Nicolas Meyer,
- Anne-Bénédicte Duval-Modeste,
- Laure Cesaire,
- Ève-Marie Neidhardt,
- Élodie Archier,
- Brigitte Dréno,
- Candice Lesage,
- Clémence Berthin,
- Nora Kramkimel,
- Florent Grange,
- Julie de Quatrebarbes,
- Pierre-Emmanuel Stoebner,
- Nicolas Poulalhon,
- Jean-Philippe Arnault,
- Safia Abed,
- Bertille Bonniaud,
- Sophie Darras,
- Valentine Heidelberger,
- Suzanne Devaux,
- Marie Moncourier,
- Laurent Misery,
- Sandrine Mansard,
- Maxime Etienne,
- Florence Brunet-Possenti,
- Caroline Jacobzone,
- Romain Lesbazeilles,
- François Skowron,
- Julia Sanchez,
- Stéphanie Catala,
- Mahtab Samimi,
- Youssef Tazi,
- Dominique Spaeth,
- Caroline Gaudy-Marqueste,
- Olivier Collard,
- Raoul Triller,
- Marc Pracht,
- Marc Dumas,
- Lucie Peuvrel,
- Pierre Combe,
- Olivier Lauche,
- Pierre Guillet,
- Yves Reguerre,
- Ingrid Kupfer-Bessaguet,
- David Solub,
- Amélie Schoeffler,
- Christophe Bedane,
- Gaëlle Quéreux,
- Sophie Dalac,
- Laurent Mortier,
- Ève Maubec
Affiliations
- Candice Hober
- Centre Hospitalier Universitaire (CHU) de Lille, 59037 Lille, France
- Lisa Fredeau
- Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris (APHP), 93000 Bobigny, France
- Anne Pham-Ledard
- CHU de Bordeaux and University of Bordeaux, 33000 Bordeaux, France
- Marouane Boubaya
- Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris (APHP), 93000 Bobigny, France
- Florian Herms
- Hôpital Saint-Louis, APHP, 75010 Paris, France
- Philippe Celerier
- CH Saint-Louis de la Rochelle, 17000 La Rochelle, France
- François Aubin
- Université de Bourgogne–Franche-Comté and CHU de Besançon, 25000 Besançon, France
- Nathalie Beneton
- CH du Mans, 72037 Le Mans, France
- Monica Dinulescu
- Hôpital Pontchaillou, 35000 Rennes, France
- Arnaud Jannic
- Hôpital Henri-Mondor, APHP, 94000 Créteil, France
- Nicolas Meyer
- Institut Universitaire du Cancer de Toulouse, 31100 Toulouse, France
- Anne-Bénédicte Duval-Modeste
- Hôpital Charles-Nicolle, 76038 Rouen, France
- Laure Cesaire
- Hôpital Côte-de-Nacre, 14000 Caen, France
- Ève-Marie Neidhardt
- Centre Léon-Bérard, 69008 Lyon, France
- Élodie Archier
- Hôpital Saint-Joseph, 13008 Marseille, France
- Brigitte Dréno
- CHU de Nantes and Université de Nantes, 44000 Nantes, France
- Candice Lesage
- CHU de Montpellier, 34295 Montpellier, France
- Clémence Berthin
- CHU d’Angers, 49100 Angers, France
- Nora Kramkimel
- APHP, Hôpital Cochin, 75014 Paris, France
- Florent Grange
- CHU de Reims, 51092 Reims, France
- Julie de Quatrebarbes
- CH Annecy Genevois, 74370 Annecy, France
- Pierre-Emmanuel Stoebner
- CHU de Nîmes, 30900 Nîmes, France
- Nicolas Poulalhon
- Hôpital Lyon Sud–Hospices Civils de Lyon, 69310 Lyon, France
- Jean-Philippe Arnault
- CHU Amiens-Picardie, 80000 Amiens, France
- Safia Abed
- Hôpital d’Instruction des Armées Sainte-Anne, 83000 Toulon, France
- Bertille Bonniaud
- CHU F.-Mitterrand Dijon-Bourgogne, 21000 Dijon, France
- Sophie Darras
- CH de Boulogne-sur-Mer, 62200 Boulogne-sur-Mer, France
- Valentine Heidelberger
- CH Robert-Ballanger, 93600 Aulnay-sous-Bois, France
- Suzanne Devaux
- CH Côte Basque, 64109 Bayonne, France
- Marie Moncourier
- CHU de Grenoble-Alpes, 38700 Grenoble, France
- Laurent Misery
- CHU de Brest and University of Bretagne Occidentale, 29200 Brest, France
- Sandrine Mansard
- CHU de Clermont-Ferrand, 63100 Clermont-Ferrand, France
- Maxime Etienne
- CH de Cornouaille, CH Intercommunal de Quimper, 29000 Quimper, France
- Florence Brunet-Possenti
- APHP, Hôpital Bichat, 75018 Paris, France
- Caroline Jacobzone
- Hôpital du Scorff, 56322 Lorient, France
- Romain Lesbazeilles
- CHU de Poitiers, 86021 Poitiers, France
- François Skowron
- CH de Valence, 26000 Valence, France
- Julia Sanchez
- CHU de Reims, 51092 Reims, France
- Stéphanie Catala
- Clinique Saint-Pierre, 66000 Perpignan, France
- Mahtab Samimi
- CH Régional Universitaire Trousseau de Tours, 37170 Chambray les Tours, France
- Youssef Tazi
- Clinique Sainte-Anne, 67000 Strasbourg, France
- Dominique Spaeth
- Centre d’Oncologie de Gentilly, 54000 Nancy, France
- Caroline Gaudy-Marqueste
- University of Aix—Marseille and CHU de la Timone, 13005 Marseille, France
- Olivier Collard
- Institut de Cancérologie de la Loire–Lucien-Neuwirth (ICLN), 42270 Saint-Priest-en-Jarez, France
- Raoul Triller
- Institut Franco-Britannique, 92300 Levallois-Perret, France
- Marc Pracht
- Groupe Hospitalier de St-Malo, 35400 St-Malo, France
- Marc Dumas
- CH René-Dubos, 95300 Pontoise, France
- Lucie Peuvrel
- Institut de Cancérologie de l’Ouest, 44800 Saint-Herblain, France
- Pierre Combe
- Pôle Santé Léonard-de-Vinci, 37170 Chambray-les-Tours, France
- Olivier Lauche
- Clinique Clémentville, 34070 Montpellier, France
- Pierre Guillet
- Hôpital Privé Toulon Hyères Saint-Jean, 83100 Toulon, France
- Yves Reguerre
- CHU de Saint-Denis, 97400 Saint-Denis de la Réunion, France
- Ingrid Kupfer-Bessaguet
- CH de Niort, 79000 Niort, France
- David Solub
- Hôpital Louis Pasteur, 28630 Le Coudray, France
- Amélie Schoeffler
- CH Régional Metz-Thionville, 57100 Metz, France
- Christophe Bedane
- CHU F.-Mitterrand Dijon-Bourgogne, 21000 Dijon, France
- Gaëlle Quéreux
- CHU de Nantes and Université de Nantes, 44000 Nantes, France
- Sophie Dalac
- CHU F.-Mitterrand Dijon-Bourgogne, 21000 Dijon, France
- Laurent Mortier
- Centre Hospitalier Universitaire (CHU) de Lille, 59037 Lille, France
- Ève Maubec
- Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris (APHP), 93000 Bobigny, France
- DOI
- https://doi.org/10.3390/cancers13143547
- Journal volume & issue
-
Vol. 13,
no. 14
p. 3547
Abstract
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%; partial, 29%). With median follow-up at 12.6 months, median PFS was 7.9 months, and median OS and DOR were not reached. One-year OS was 73% versus 36%, respectively, for patients with PS < 2 versus ≥ 2. Multivariate analysis retained PS ≥ 2 as being associated during the first 6 months with PFS and OS. Head-and-neck location was associated with longer PFS. Immune status had no impact. Severe treatment-related adverse events occurred in 9% of the patients, including one death from toxic epidermal necrolysis. Cemiplimab real-life safety and efficacy support its use for la/mCSCCs. Patients with PS ≥ 2 benefited less from cemiplimab, but it might represent an option for immunocompromised patients.
Keywords
- PD-1–blocking antibody
- cemiplimab
- cutaneous squamous cell carcinoma
- real-life setting
- immunocompromised
- chronic dermatosis